Clinical trials
Nephropathy clinical trials
Below are recruiting nephropathy clinical trials, each written for real people, not researchers. We’re tracking 151 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07404436RecruitingPhase 4
Blood thinner to prevent clots in kidney disease
This trial tests whether the blood thinner rivaroxaban can prevent dangerous blood clots in people with a kidney condition called membranous nephropathy who have low albumin levels and are at high risk for clots.
Beijing, Beijing MunicipalityAges 18–80 - NCT06819826RecruitingPhase 3
Study of SC0062 for IgA Nephropathy with Proteinuria
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
Guangzhou, Yuexiu DistrictAges 18 years+ - NCT07396155RecruitingPhase 1/Phase 2
Stem cell therapy for diabetic kidney disease
This trial tests whether stem cells from donated umbilical cords can safely help people with type 2 diabetes who also have kidney damage. It aims to see if this therapy can improve kidney function.
YogyakartaAges 30–65 - NCT07375758RecruitingPhase 1/Phase 2
Testing MIL116 in healthy people and those with IgA Nephropathy
This study tests a new drug called MIL116 for IgA Nephropathy. First, healthy volunteers will test the drug's safety, then people with IgA Nephropathy will see if it can help reduce protein in their urine.
BeijingAges 18 years+ - NCT07354932RecruitingPhase 2
Testing SHR-2173 for IgA Nephropathy
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
Guangzhou, GuangdongAges 18 years+ - NCT07289763RecruitingPhase 2
Study of SHR-2173 for primary membranous nephropathy
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
Nanjing, JiangsuAges 18–75 - NCT07266181RecruitingPhase 1
CAR-T cell therapy for tough-to-treat membranous nephropathy
This trial tests whether specially engineered immune cells (CAR-T cells) can help people with a kidney condition called primary membranous nephropathy that has not improved with standard treatments. The goal is to see if this therapy can reduce protein in the urine and protect kidney function.
Xi'an, ChinaAges 18 years+ - NCT04662723RecruitingPhase 4
Personalized treatment for IgA kidney disease
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
Bari, BAAges 18 years+ - NCT01802034Recruiting
Study kidney samples to understand autoimmune, inflammatory, and diabetic disease
This trial collects and studies kidney tissue samples to better understand what drives kidney problems linked to autoimmune, inflammation, and diabetes. Your participation may help researchers develop better ways to diagnose and treat these conditions.
New York, New YorkAges 18 years+ - NCT06740526RecruitingPhase 2
A trial of sibeprenlimab for IgA nephropathy kidney tissue
This study tests a drug called sibeprenlimab to see how it affects kidney tissue in people with IgA nephropathy (IgAN), a condition where antibodies build up in the kidneys. It may help protect your kidneys if your disease is still active.
Denver, ColoradoAges 16 years+ - NCT07204275RecruitingPhase 2/Phase 3
Testing povetacicept for primary membranous nephropathy
This study tests an investigational drug called povetacicept for people with primary membranous nephropathy, a kidney disease. Researchers want to see if it is safe and helps reduce protein in the urine.
Montgomery, AlabamaAges 18–75 - NCT06843304Recruiting
Diabetes kidney disease prevention and control study
This trial tests a new system to manage diabetic kidney disease across all stages. It is for people with type 2 diabetes who either have no kidney damage or have kidney damage confirmed by a biopsy.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07187713RecruitingPhase 4
Study of ACE Reno, Pico Cell Matrix for kidney health
This trial tests a new treatment called ACE Reno, Pico Cell Matrix to see if it can improve kidney function in people with chronic kidney disease (CKD) at various stages. It may be an option if you have early to moderate kidney issues (including after a transplant) and are already on standard therapies.
Giza, GZAges 18–80 - NCT07182227RecruitingPhase 1/Phase 2
Gene therapy for IgA nephropathy kidney disease
This trial tests a new gene therapy called PS-002 for adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The treatment aims to reduce kidney damage, and this study will help determine if it is safe and effective.
Miami, FloridaAges 18 years+ - NCT07163611RecruitingPhase 2/Phase 3
Obinutuzumab for PLA2R antibodies in membranous nephropathy
This study is testing a drug called obinutuzumab to see if it can lower PLA2R antibodies in people with membranous nephropathy (a kidney disease). The goal is to reduce protein leakage in urine and improve kidney health.
NijmegenAges 18 years+ - NCT07157787RecruitingPhase 2
Testing a new drug for primary membranous nephropathy
This trial tests a new drug called ALXN1920 for adults with primary membranous nephropathy (PMN), a kidney disease where the immune system attacks the kidneys. It is for people at high risk of their disease getting worse, and it compares the new drug added to standard care versus standard care alone.
Loma Linda, CaliforniaAges 18–75 - NCT07146906RecruitingPhase 2
Study of zigakibart for IgA nephropathy
This trial tests a new drug called zigakibart for people with IgA nephropathy, a kidney disease. It aims to see if the drug can help reduce protein in the urine and protect kidney function.
Denver, ColoradoAges 18–100 - NCT07135219Enrolling by invitationEarly Phase 1
Study of cizutamig for IgA nephropathy
This trial tests a new drug called cizutamig for people with IgA nephropathy who still have high protein in their urine despite trying other treatments. It aims to see if the drug can help protect kidney function.
BeijingAges 18–75 - NCT07096843RecruitingPhase 2
Study of Budoprutug for Primary Membranous Nephropathy
This trial tests an investigational drug called budoprutug for people with primary membranous nephropathy, a kidney condition. The goal is to see if the drug can reduce protein in the urine and help protect kidney function.
Denver, ColoradoAges 18–75 - NCT06965764Recruiting
Contrast Dye and Kidney Health Study
This study looks at how contrast dye used in imaging tests (like CT scans) can sometimes affect the kidneys. Researchers want to track patients at Sohag University Hospitals to better understand and prevent kidney injury after receiving contrast.
SohagAges 18 years+ - NCT06695429Recruiting
Beetroot juice to prevent kidney damage from contrast dye
This trial tests if drinking beetroot juice can help protect your kidneys from damage caused by the dye used during heart procedures. It is for people hospitalized with a certain type of heart attack who are at moderate to high risk of kidney problems.
CartagenaAges 18 years+ - NCT07074951Recruiting
Tonsillectomy and immune therapy for high-risk IgA kidney disease
This trial tests whether removing the tonsils (tonsillectomy) plus immune-suppressing therapy can help people with a high-risk form of IgA nephropathy, a kidney disease. It aims to slow down kidney damage and delay the need for dialysis.
Saint PetersburgAges 18–75 - NCT06984406Recruiting
Beet product for kidney protection during heart procedure
This trial tests a beet-derived food product (a natural source of nitrate) to see if it can help prevent kidney damage caused by the contrast dye used during a heart procedure called PCI. It is designed for people who already have a higher risk of this kidney problem.
MoscowAges 18 years+ - NCT07056595Recruiting
Finerenone for IgA nephropathy patients
This trial tests whether finerenone can help people with IgA nephropathy, a kidney disease. It is for adults with high protein in their urine who are already on standard kidney-protecting medications.
MoscowAges 18 years+
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nephropathy?
- Yes. Clin2 currently lists 151 recruiting nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.